Insider Selling: AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) EVP Sells 71,694 Shares of Stock

Key Points

• Amneal Pharmaceuticals' EVP, Nikita Shah, sold 71,694 shares of stock valued at $666,037.26, reducing ownership by 21.15%.
• The company's stock has a current trading price of $9.45 and has a market capitalization of $2.96 billion.
• Amneal Pharmaceuticals beat earnings projections with $0.23 earnings per share, surpassing analysts' expectations of $0.17.

AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 71,694 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $9.29, for a total transaction of $666,037.26. Following the sale, the executive vice president directly owned 267,235 shares in the company, valued at $2,482,613.15. This trade represents a 21.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Nikita Shah also recently made the following trade(s):

• On Tuesday, August 12th, Nikita Shah sold 50,000 shares of AMNEAL PHARMACEUTICALS stock. The shares were sold at an average price of $9.04, for a total value of $452,000.00.

AMNEAL PHARMACEUTICALS Stock Up 0.9%

Shares of NASDAQ:AMRX traded up $0.08 during midday trading on Wednesday, reaching $9.41. The company had a trading volume of 1,635,717 shares, compared to its average volume of 1,633,172. AMNEAL PHARMACEUTICALS, INC. has a 1-year low of $6.68 and a 1-year high of $9.59. The stock has a market cap of $2.96 billion, a PE ratio of 941.94 and a beta of 1.11. The business's 50 day moving average price is $8.31 and its 200 day moving average price is $7.99.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, research analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AMRX shares. The Goldman Sachs Group started coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen downgraded shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, AMNEAL PHARMACEUTICALS has an average rating of "Buy" and a consensus target price of $11.60.

Institutional Trading of AMNEAL PHARMACEUTICALS

Hedge funds have recently modified their holdings of the stock. Nuveen LLC acquired a new position in AMNEAL PHARMACEUTICALS in the 1st quarter valued at about $19,581,000. Nantahala Capital Management LLC grew its position in shares of AMNEAL PHARMACEUTICALS by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after purchasing an additional 995,586 shares during the last quarter. Rubric Capital Management LP increased its stake in shares of AMNEAL PHARMACEUTICALS by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock worth $94,737,000 after purchasing an additional 974,355 shares during the period. Woodline Partners LP lifted its holdings in AMNEAL PHARMACEUTICALS by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company's stock worth $12,604,000 after purchasing an additional 937,035 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in AMNEAL PHARMACEUTICALS by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after purchasing an additional 920,758 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.